Clinical Trials Browser

INDUSTRY × Bites and Stings × AMG 757 × Clear all

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma